Pharmaceuticals
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
SUZHOU, China and MÖLNDAL, Sweden, July 2, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL) announce the successful...
2026-07-02 09:29
972
Vitafoods Asia 2026: Science-Backed Botanicals and Next-Generation Probiotics Take Centre Stage
Leading Companies Present Science-Backed Solutions Addressing Antimicrobial Resistance, Digestive Health, and Wellness Through Advanced Probiotics and Clinical Botanicals BANGKOK, July 1, 2026 /PRNewswire/ -- As global healthcare confronts the urgent challenge of antimicrobial resistance, Vitafo...
2026-07-01 18:37
2087
Shantha Biologics Announces Cartridge Fill-Finish Collaboration
HYDERABAD, India, June 30, 2026 /PRNewswire/ -- Shantha Biologics today announced that it has entered into an outsourcing agreement with Novo Nordisk to provide cartridge fill-finish manufacturing services in India. The agreement with Novo Nordisk reflects Shantha Biologics' continued focus on h...
2026-06-30 21:47
1476
Alebund Pharmaceuticals (09637.HK) Debuts on the HKEx Main Board
Deepening Its Commitment to Kidney Disease and Accelerating Toward Becoming a Global Leader in Renal Innovation SHANGHAI, June 29, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a biopharmaceutical company focused on kidney dise...
2026-06-29 20:00
2152
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
* Recommendation follows an Article 20 non-pharmacovigilance procedure * Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the...
2026-06-26 21:06
3726
Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia
SHANGHAI, June 26, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China's National Medical Products...
2026-06-26 10:08
1733
Haier Biomedical Debuts Innovative Automated Low-Carbon Cold Storage Products at Two Major Global Industry Trade Fairs
From Europe Biobank Week 2026 in Prague to Interphex Week Tokyo 2026, Haier
Biomedical continuously strengthens global life sciences market presence
through localized innovative products and profound ecosystem partnerships
QINGDAO, China, June 25, 2026 /PRNewswire/ -- Haier Biomedical
2026-06-25 17:34
1778
ATLATL and Samsung Bioepis Launch 'Samsung Bioepis Innovation Prize C-Lab Outside' to Accelerate Early-Stage Biotech Innovation Across Asia-Pacific
Applications Open June 25 for Early-Stage Biotech Companies Developing Next-Generation Therapeutics and Platform Technologies SHANGHAI, June 25, 2026 /PRNewswire/ -- ATLATL Innovation Center ("ATLATL"), a global innovation platform for life science research and development, and Samsung Bioepis C...
2026-06-25 07:30
1970
Abu Dhabi Announces Partnership with MSD to Advance Operational Excellence and Expand Access across the Region
ABU DHABI, UAE, June 25, 2026 /PRNewswire/ -- As healthcare systems worldwide seek more resilient and efficient pathways to deliver innovative medicines, the Department of Health – Abu Dhabi (DoH) has announced a collaboration with global pharmaceutical leader MSD (Merck & Co., Inc., Rahway, New...
2026-06-25 03:15
1586
Tarek Samad appointed EVP, Head of Research & Development at Lundbeck
VALBY, Denmark, June 24, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head of Research & Development (R&D) and will join the Executive Leadership Team (ELT) effective 1 September 2026. Tarek Samad succeeds Johan ...
2026-06-24 18:19
1545
Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026
* Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment, bocunebart * Eptinezumab data explore patient-centered outcomes in chronic migra...
2026-06-24 16:08
1195
Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules
SHANGHAI, June 24, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Everest Medicines and Hainan He...
2026-06-24 15:07
1801
Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026
SHENZHEN, China, June 24, 2026 /PRNewswire/ -- From June 16 to 18, the CPHI & PMEC China 2026 was held at the Shanghai New International Expo Center. Kexing Biopharm (688136.SH) showcased multiple self-developed innovative drug pipelines and over 30 products for international markets at the exhib...
2026-06-24 11:53
1099
EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services
PROVIDENCE, R.I., June 23, 2026 /PRNewswire/ -- EpiVax, Inc., a recognized leader in immunogenicity risk assessment, announces the expansion of its laboratory facilities at its Providence, RI headquarters. The upgraded space has more than doubled the company's laboratory footprint, expanding the ...
2026-06-23 21:12
934
Fair Play Menarini International Award
Diego Milito and Emilio Butragueño among the winners of the 30th edition FLORENCE, Italy, June 23, 2026 /PRNewswire/ -- The list of winners of the 30th Fair Play Menarini International Award, scheduled forJuly 2 in Florence, continues to include great legends of world sport. Among the champions w...
2026-06-23 18:29
1008
Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity
* Phase I trial consists of two parts. Part A is a single ascending dose (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part B is a head-to-head study of multiple ascending doses (MAD) of ASC35 once-monthly SALD formulation compared to the U.S. Food and Drug ...
2026-06-23 18:10
1507
CPHI/ Hi Korea 2026 Opens Pre-Registration: Korea's Hub for Pharma, Biopharma, and Health Innovation
SEOUL, South Korea, June 23, 2026 /PRNewswire/ -- Informa Markets Korea has
officially opened pre-registration for CPHI/ Hi Korea 2026, taking place at
COEX, Seoul, from August 25 to 27. Pre-registered visitors enjoy complimentary
entries.
2026-06-23 08:00
2854
DoH and Sanofi Partner to Advance Vaccine Innovation
ABU DHABI, UAE, June 23, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Sanofi, a worldwide biopharma and vaccines leader, have signed an Memorandum of Understanding and intend to into an agreement to advance their partner...
2026-06-23 07:47
2907
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address ...
2026-06-23 05:37
3240
Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)
* European approval is based on results from the Phase 3 BREAKWATER trial, which demonstrated that encorafenib in combination with cetuximab and mFOLFOX6 demonstrated a statistically significant improvement in the dual primary endpoints of objective response rate (ORR) and progression-free sur...
2026-06-22 21:14
1690
Week's Top Stories
Most Reposted
Visa redefines its role in travel with the global expansion of Visa Destinations
[Picked up by 336 media titles]
2026-06-30 10:00Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 323 media titles]
2026-06-29 12:41
Agoda rolls out suite of new features focused on real-time updates and smarter trip planning
[Picked up by 321 media titles]
2026-07-01 10:00
On-us Brings Real-Time Smart E-Vouchers to Google Wallet, Giving Marketers a Live Read on Customer Behavior
[Picked up by 318 media titles]
2026-06-30 11:00
Avnet Brings Ecosystem Together to Scale Edge AI in Singapore
[Picked up by 305 media titles]
2026-06-30 09:00Most Read
Farmmi, Inc. Announces Launch of Proposed Public Offering
2026-06-27 08:01
4632
Korean Skincare Brand Meditherapy Tops Amazon U.S. Facial Serums, Breaking Into Beauty Best Sellers Top 20
2026-06-26 21:00
4430
Trip.com Group Limited Reports Unaudited First Quarter of 2026 Financial Results
2026-06-25 06:00
4385
E Fund (HK) HKEX Tech 100 Index ETF (3456) Lists Today
2026-06-26 17:19
4275
